<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260612246187/en/FDA-Approves-KEYTRUDA%C2%AE-pembrolizumab-and-KEYTRUDA-QLEX%E2%84%A2-pembrolizumab-and-berahyaluronidase-alfa-pmph-Each-With-WELIREG%C2%AE-belzutifan-for-Adjuvant-Treatment-of-Certain-Patients-With-Clear-Cell-Renal-Cell-Carcinoma-ccRCC/">FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)</a>
    </div>

      <div class="me-0 me-md-5">
        RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA® and KEYTRUDA QLEXTM , Each With WELIREG®, for Adjuvant Treatment of Certain Patients With ccRCC.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">ETF Trends</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.etftrends.com/thematic-investing-content-hub/healthcare-etfs-broad-exposure-breakthroughs/">Healthcare ETFs: From Broad Exposure to Big Breakthroughs</a>
    </div>

      <div class="me-0 me-md-5">
        With AI and space dominating many of the market&#39;s most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260610672968/en/Merck-Animal-Health-to-Acquire-TARGAN/">Merck Animal Health to Acquire TARGAN</a>
    </div>

      <div class="me-0 me-md-5">
        RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck &amp; Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Forbes</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.forbes.com/sites/brucejapsen/2026/06/09/trouble-ahead-for-glp-1-drugs-as-health-plans-stop-paying/">Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying</a>
    </div>

      <div class="me-0 me-md-5">
        More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260608276598/en/Gilead-and-Merck-Announce-Positive-Topline-Results-From-Two-Phase-3-Studies-Evaluating-IslatravirLenacapavir-an-Oral-Once-Weekly-HIV-Treatment/">Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment</a>
    </div>

      <div class="me-0 me-md-5">
        FOSTER CITY, Calif., &amp; RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The I...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260608789974/en/Merck-and-Gilead-Provide-Update-on-Phase-3-KEYNOTE-D46EVOKE-03-Study/">Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study</a>
    </div>

      <div class="me-0 me-md-5">
        RAHWAY, N.J. &amp; FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead&#39;s Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck&#39;s anti-PD-1 therapy, co...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Merck-DE0006599905">Merck</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260602690569/en/Rejuvenate-Bio-Announces-6-Million-Financing-and-Strategic-RD-Collaboration-with-Merck-Animal-Health/">Rejuvenate Bio Announces $6 Million Financing and Strategic R&amp;D Collaboration with Merck Animal Health</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO--(BUSINESS WIRE)-- #animalhealth--Rejuvenate Bio Announces $6 Million Financing and Strategic R&amp;D Collaboration with Merck Animal Health.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Merck-DE0006599905/load_more?page=10">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>